Technology to control extracellular matrix remodeling in disease

Albatroz Therapeutics is pioneering the development of first-in-class therapeutic antibodies aimed at a novel target, Calnexin, which plays a crucial role in the degradation of the extracellular matrix. This degradation is a significant factor in the progression of various diseases, including aggressive cancers and inflammatory conditions. By blocking Calnexin, Albatroz's antibodies aim to prevent tumor growth, metastasis, and recurrence, particularly in challenging cancers such as pancreatic, lung, and liver cancers. The company emphasizes that their therapeutic approach is designed to improve treatment outcomes without the toxicity commonly associated with existing therapies, demonstrating efficacy in tumor models without detectable adverse effects.

In addition to cancer, Albatroz is also focused on addressing the challenges posed by arthritis and Inflammatory Bowel Disease (IBD). Their therapeutic antibodies are being developed to prevent the destruction of joint cartilage in arthritis, thereby halting disease progression and promoting healing. Similarly, for IBD, the company aims to mitigate chronic inflammation and tissue damage in the intestines, enhancing the quality of life for patients suffering from conditions like Crohn’s disease and ulcerative colitis. Overall, Albatroz Therapeutics is committed to creating innovative, non-toxic treatments that target the underlying mechanisms of these diseases, offering hope for improved patient outcomes.

Singapore

Albatroz Therapeutics is a pre-clinical stage biotech company developing therapeutic antibodies and ADCs to treat solid tumours and arthritis, based on its proprietary position over a novel target critical to ECM degradation.

Albatroz Therapeutics

Company Details